Overview of the Regulatory Framework and FDA’s Guidance on the Development and Approval of Biosimilar Products in the US

Leah Christl, Ph.D.
Associate Director for Therapeutic Biologics
OND Therapeutic Biologics and Biosimilars Team/CDER/FDA
Overview of Presentation

• Overview
  – Background
  – Terminology
  – Approval Pathway for Biosimilars – General Requirements

• Development of Biosimilars
  – Approach to Development
  – Specific Development Concepts
Overview of the BPCI Act
Background

• The Biologics Price Competition and Innovation Act of 2009 (BPCI Act) was signed into law on March 23, 2010.

• BPCI Act creates an **abbreviated licensure pathway for biological products shown to be biosimilar to or interchangeable with** an FDA-licensed reference product.
  
  – A biological product that is demonstrated to be “**highly similar**” to an FDA-licensed biological product (the reference product) may rely for licensure on, among other things, publicly-available information regarding FDA’s previous determination that the reference product is safe, pure and potent.
  
  – This licensure pathway permits a biosimilar biological product to be licensed under 351(k) of the Public Health Service Act (PHS Act) based on **less than a full complement of product-specific preclinical and clinical data → abbreviated licensure pathway**.
What is Meant by Abbreviated Licensure Pathway?

• The abbreviated licensure pathway does not mean that a lower approval standard is applied to biosimilar or interchangeable products than to originator biological products.

• The ability to rely on FDA’s previous finding regarding the reference product to support approval of the biosimilar product allows for a potentially shorter and less costly drug development program. This is what is meant by an abbreviated licensure pathway.

• The **data package** required for approval of a biosimilar or interchangeable product is quite extensive; biosimilar applicants submit data from analytical, nonclinical, and clinical studies to support a demonstration of biosimilarity with the reference product.

• Once a biosimilar or interchangeable has been approved by FDA, patients and health care providers will be able to rely upon the safety and effectiveness of an FDA-approved biosimilar or interchangeable product just as they would for the reference product that the biosimilar was compared to.
Biosimilarity

Biosimilar or Biosimilarity means:

- that the biological product is **highly similar** to the reference product notwithstanding minor differences in clinically inactive components; and

- there are **no clinically meaningful differences** between the biological product and the reference product in terms of the safety, purity, and potency of the product.
Reference Product

Reference Product:

- the **single biological product, licensed under section 351(a) of the PHS Act**, against which a biological product is evaluated in an application submitted under section 351(k) of the PHS Act.

- An application submitted under section 351(a) of the PHS Act is a “stand-alone” application that contains all information and data necessary to demonstrate that the proposed product is safe, pure and potent.

- In contrast, an application submitted under section 351(k) needs to demonstrate that the proposed product is biosimilar to the reference product. For licensure, a proposed biosimilar relies on (among other things) comparative data with the reference product, as well as publicly-available information regarding FDA’s previous determination that the reference product is safe, pure and potent.
Interchangeability

Interchangeable or Interchangeability:

- the biological product is **biosimilar** to the reference product;
- it **can be expected** to produce the **same clinical result** as the reference product **in any given patient**; and
- for a product that is administered more than once to an individual, the risk in terms of **safety or diminished efficacy of alternating or switching** between use of the product and its reference product is not greater than the risk of using the reference product without such alternation or switch.

An interchangeable product **may be substituted** for the reference product without the intervention of the health care provider who prescribed the reference product.
General Requirements

A 351(k) application must include information demonstrating that the biological product:

- Is **biosimilar** to a reference product;
- Utilizes the **same mechanism(s) of action** for the proposed condition(s) of use -- but only to the extent the mechanism(s) are known for the reference product;
- **Condition(s) of use** proposed in labeling **have been previously approved** for the reference product;
- Has the **same route of administration, dosage form, and strength** as the reference product; and
- Is manufactured, processed, packed, or held in a facility that **meets standards** designed to assure that the biological product continues to be safe, pure, and potent.
General Data Elements: 351(k) Application

The PHS Act requires that a 351(k) application include, among other things, information demonstrating biosimilarity based upon data derived from:

- **Analytical studies** demonstrating that the biological product is “highly similar” to the reference product notwithstanding minor differences in clinically inactive components;

- **Animal studies** (including the assessment of toxicity); and

- A **clinical study or studies** (including the assessment of immunogenicity and pharmacokinetics (PK) or pharmacodynamics (PD)) that are sufficient to demonstrate safety, purity, and potency in 1 or more appropriate conditions of use for which the reference product is licensed and for which licensure is sought for the biosimilar product.

FDA may determine, in its discretion, that an element described above is unnecessary in a 351(k) application.
Use of Non-US-Licensed Comparator Products

• The PHS Act defines the “reference product” for a 351(k) application as the “single biological product licensed under section 351(a) against which a biological product is evaluated.”

• Data from animal studies and certain clinical studies comparing a proposed biosimilar product with a non-US-licensed product may be used to support a demonstration of biosimilarity to a US-licensed reference product.

• Sponsor should provide adequate data or information to scientifically justify the relevance of these comparative data to an assessment of biosimilarity and to establish an acceptable bridge to the U.S.-licensed reference product.
Support for Use of Non-US-Licensed Comparator

- Type of bridging data needed would include:
  - Direct physicochemical comparison of all 3 products (proposed biosimilar to US-licensed reference product; proposed biosimilar to non-US-licensed comparator product; US-licensed reference product to non-US-licensed comparator product)
  - Likely 3-way bridging clinical PK and/or PD study
  - All three pair-wise comparisons should meet the pre-specified acceptance criteria for analytical and PK and/or PD similarity.

- A sponsor should justify the extent of comparative data needed to establish a bridge to the U.S.-licensed reference product.
Overview of FDA’s Approach to the Development of Biosimilars
FDA Guidance

1. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product (final, 2015)
2. Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product (final, 2015)
4. Formal Meetings Between the FDA and Biosimilar Biological Product Sponsors or Applicants (final, 2015)
5. Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product (final, 2016)
7. Reference Product Exclusivity for Biological Products Filed Under Section 351(a) of the PHS Act (draft, 2014)
9. Labeling for Biosimilar Products (draft, 2016)
10. Considerations in Demonstrating Interchangeability With a Reference Product (draft, 2017)

http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm290967.htm
Key Development Concepts
Key Concept #1: Goals of “Stand-alone” and Biosimilar Development are Different

“Stand-alone” Development Program, 351(a)
Goal: To establish safety and efficacy of a new product

“Abbreviated” Development Program, 351(k)
Goal: To demonstrate biosimilarity (or interchangeability) to a reference product

What does this difference mean from a development perspective?
Key Concept #2: Stepwise Evidence Development

- FDA has outlined a **stepwise approach** to generate data in support of a demonstration of biosimilarity.

- Evaluation of residual uncertainty at each step of data generation.

- *Totality-of-the-evidence* approach in evaluating biosimilarity.

- There is no one “pivotal” study that demonstrates biosimilarity.
No “one size fits all” assessment

• Apply a step-wise approach to data generation and the evaluation of residual uncertainty*

Analytical Studies

Animal Studies

Clinical PK/PD Studies

Clinical Immunogenicity Assessment

Additional Clinical Studies

• What differences have been observed and what is the potential impact?
• What is the residual uncertainty and what study(ies) will address the residual uncertainty?

* The list is not intended to imply that all types of data described here are necessary for any given biosimilar development program. FDA may determine, in its discretion, that certain studies are unnecessary in a 351(k) application.
Key Concept #3: Analytical Similarity Data - The Foundation of a Biosimilar Development Program

• Extensive **structural and functional characterization**
• Protein Heterogeneity
• Lot-to-lot variability
• All need to be evaluated as part of analytical similarity studies
Assessing Analytical Similarity

• Comprehensive structural and functional analyses
• Comparative assessment of attributes including:
  – Amino acid sequence and modifications
  – Folding
  – Subunit interactions
  – Heterogeneity (size, aggregates, charge, hydrophobicity)
  – Glycosylation
  – Bioactivity
  – Impurities
• If a molecule is known to have multiple biological activities, where feasible, each should be demonstrated to be highly similar between the proposed biosimilar product and the reference product
• **Understand** the molecule and function and identify **critical quality attributes**
Generating Analytical Similarity Data

• Characterize reference product quality characteristics and product variability

• Manufacturing process for the proposed biosimilar product should be designed to produce a product with minimal or no difference in product quality characteristics compared to the reference product

• Identify and evaluate the potential impact of differences observed and what study(ies) will address the residual uncertainty

• **Understanding the relationship** between quality attributes and the clinical safety & efficacy profile aids ability to determine **residual uncertainty** about biosimilarity and to predict expected “clinical similarity” from the quality data.
Statistical Analysis of Analytical Similarity Data

• Statistical analyses of the analytical similarity data are conducted to support a demonstration that the proposed biosimilar product is highly similar to the reference product

• Quality attributes are ranking based on criticality with regard to their potential impact on activity, PK/PD, safety, immunogenicity, and other factors

• Data are then analyzed by various testing methodologies
Animal Data

• Animal toxicity data are useful when uncertainties remain about the safety of the proposed product prior to initiating clinical studies.

• The scope and extent of animal studies, including toxicity studies, will depend on publicly available information and/or data submitted in the biosimilar application regarding the reference product and the proposed biosimilar product, and the extent of known similarities or differences between the two.

• A comparison of PK/PD in an animal model may be useful.
Key Concept # 4: Role of Clinical Studies

• The nature and scope of clinical studies will depend on the extent of residual uncertainty about the biosimilarity of the two products after conducting structural and functional characterization and, where relevant, animal studies.

"Abbreviated" Development Program, 351(k) BLA
Type of Clinical Data

• As a scientific matter, FDA expects an adequate clinical PK, and PD if relevant, comparison between the proposed biosimilar product and the reference product.

• As a scientific matter, at least 1 clinical study that includes a comparison of the immunogenicity of the proposed and reference product generally will be expected.

• As a scientific matter, a comparative clinical study will be necessary to support a demonstration of biosimilarity if there are residual uncertainties about whether there are clinically meaningful differences between the proposed and reference products based on structural and functional characterization, animal testing, human PK and PD data, and clinical immunogenicity assessment.
Comparative Human PK and PD Data

• PK and/or PD is generally considered the most sensitive clinical study/assay in which to assess for differences between products, should they exist

• PK
  – Demonstrate PK similarity in an adequately sensitive population to detect any differences, should they exist

• PD
  – Similar PD using PD measure(s) that reflects the mechanism of action (MOA) or reflects the biological effect(s) of the drug

• PK and PD similarity data supports a demonstration of biosimilarity with the assumption that similar exposure (and pharmacodynamic response, if applicable) will provide similar efficacy and safety (i.e., an exposure-response relationship exists)
Comparative Clinical Study

• A comparative clinical study for a biosimilar development program should be designed to investigate whether there are clinically meaningful differences in safety and efficacy between the proposed product and the reference product.

• Population, endpoint, sample size and study duration should be adequately sensitive to detect differences, should they exist.

• Typically, an equivalence design would be used, but other designs may be justified depending on product-specific and program-specific considerations.

• Assessment of safety and immunogenicity
Key Concept # 5: Extrapolation

• The potential exists for a biosimilar product to be approved for one or more conditions of use for which the reference product is licensed based on extrapolation
• Sufficient scientific justification for extrapolation is necessary
• Differences between conditions of use (e.g., indications) do not necessarily preclude extrapolation
• FDA guidance outlines factors to consider, including:
  – MoA in each condition of use
  – PK and biodistribution in different patient populations
  – Immunogenicity in different patient populations
  – Differences in expected toxicities in each condition of use and patient population
Extrapolation Considerations: “Stand-alone” Drug Development

- Clinical Safety & Efficacy
  - Clinical Pharmacology
  - Non-clinical
  - Analytical
  - Indication 1

- Clinical Safety & Efficacy
  - Indication 2

- Clinical Safety & Efficacy
  - Indication 3

- Clinical Safety & Efficacy
  - Indication 4
Extrapolation Considerations: “Stand-alone” vs. Biosimilar Development

<table>
<thead>
<tr>
<th>Clinical Safety &amp; Efficacy</th>
<th>Clinical Safety &amp; Efficacy</th>
<th>Clinical Safety &amp; Efficacy</th>
<th>Clinical Safety &amp; Efficacy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Pharmacology</td>
<td>Indication 2</td>
<td>Indication 3</td>
<td>Indication 4</td>
</tr>
<tr>
<td>Non-clinical</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Analytical</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Extrapolation from information in 351(k) BLA and FDA’s finding for the reference product to other indications previously approved for the reference product, considering for each indication:

- MOA(s)
- PK
- Immunogenicity
- Known toxicities

Biosimilar extrapolation is based on all available data in the 351(k) BLA and FDA’s finding for the reference product, not from the indication(s) studied for biosimilar to other non-studied indications.
Summary

• Development of a biosimilar product is different from “stand-alone” product development
  – Development goal is not to re-establish safety and effectiveness but to demonstrate the biosimilar product is highly similar to the reference product, and that there are no clinically meaningful differences

• Analytical comparisons are the foundation for determining whether the products are highly similar

• Clinical PK (and/or PD) is generally considered the most sensitive endpoint for detecting differences between products; an assessment of immunogenicity is needed and comparative clinical data are collected if questions remain

• Approval of a proposed biosimilar product is based on the integration of various information and the totality of the evidence submitted by the biosimilar sponsor to provide an overall assessment that the proposed product is biosimilar to the reference product.

• The FDA’s high standard for approval of biosimilar and interchangeable products means that patients and health care professionals can be confident of the safety and effectiveness of a biosimilar or interchangeable product, just as they would for the reference product.
Thank you for your attention.

Questions?
FDA Overview

BLA 125545

“Epoetin Hospira”, a proposed biosimilar to US-licensed Epogen/Procrit

R. Angelo de Claro, MD
Medical Officer Team Leader
Division of Hematology Products
U.S. Food and Drug Administration

May 25, 2017
Proposed Indications

Same as US-licensed Epogen/Procrit:

<table>
<thead>
<tr>
<th>US-Epogen/Procrit Indications</th>
<th>Year of FDA Approval</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. For the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and not on dialysis to decrease the need for red blood cell (RBC) transfusion</td>
<td>1989</td>
</tr>
<tr>
<td>2. For the treatment of anemia due to zidovudine administered at ≤4200 mg/week in HIV-infected patients with endogenous serum erythropoietin levels of ≤ 500 mUnits/mL</td>
<td>1991</td>
</tr>
<tr>
<td>3. For the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy</td>
<td>1993</td>
</tr>
<tr>
<td>4. To reduce the need for allogeneic RBC transfusions among patients with perioperative hemoglobin &gt; 10 to ≤ 13 g/dL who are at high risk for perioperative blood loss from elective, noncardiac, nonvascular surgery</td>
<td>1996</td>
</tr>
</tbody>
</table>
Key Topics to Consider

Topic 1: highly similar notwithstanding minor differences in clinically inactive components based on evidence from analytical studies

• Use of multiple orthogonal physicochemical and functional methods
  – Primary-, secondary-, and tertiary structure
  – Post-translational modification
  – Biological activity
  – Stability profiles
Key Topics to Consider

Topic 2: no clinically meaningful differences in terms of safety, purity, and potency

- Comparative clinical studies in healthy subjects and patients with chronic kidney disease
  - Pharmacokinetics/Pharmacodynamics
  - Efficacy
  - Safety
  - Immunogenicity
“Epoetin Hospira” Clinical Studies

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Design</th>
<th>Route</th>
<th>Number</th>
<th>Subjects</th>
<th>Dose</th>
<th>Schedule</th>
<th>Primary Endpoint</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPOE-12-02</td>
<td>Cross-over</td>
<td>Subcutaneous</td>
<td>81</td>
<td>Healthy subjects</td>
<td>100 U/kg</td>
<td>Single dose</td>
<td>PK and PD similarity (reticulocyte count)</td>
</tr>
<tr>
<td>EPOE-14-01</td>
<td>Parallel</td>
<td>Subcutaneous</td>
<td>129</td>
<td>Healthy subjects</td>
<td>100 U/kg</td>
<td>3 times / week for 4 weeks</td>
<td>PD similarity (Hb)</td>
</tr>
<tr>
<td>EPOE-10-13</td>
<td>Parallel</td>
<td>Subcutaneous</td>
<td>246</td>
<td>Patients with CKD on HD</td>
<td>Variable</td>
<td>1-3 times / week</td>
<td>Mean weekly Hb Mean weekly dose</td>
</tr>
<tr>
<td>EPOE-10-01</td>
<td>Parallel</td>
<td>Intravenous</td>
<td>612</td>
<td>Patients with CKD on HD</td>
<td>Variable</td>
<td>1-3 times / week</td>
<td>Mean weekly Hb Mean weekly dose</td>
</tr>
</tbody>
</table>

CKD: chronic kidney disease
HD: hemodialysis
PK: pharmacokinetics
PD: pharmacodynamics
Hb: hemoglobin
Key Topics to Consider

**Topic 3**: adequate scientific justification to support licensure for all of the proposed indications

- Scientific justification
  - Mechanism of action
  - Similarity
    - Product quality attributes
    - Pharmacokinetics/pharmacodynamics
    - Immunogenicity
    - Efficacy and safety
Key Topics to Consider

**Topic 4**: totality of evidence supports licensure of “Epoetin Hospira” as a biosimilar product to US-licensed Epogen/Procrit for the indications for which US-licensed Epogen/Procrit is currently licensed and for which the Applicant is seeking licensure (voting question)
“Epoetin Hospira”, a proposed biosimilar to US-licensed Epogen/Procrit
BLA 125545

FDA Presentation
Oncologic Drugs Advisory Committee

May 25, 2017
FDA Presentation Outline

A. Chemistry, Manufacturing, and Controls (CMC) and CMC Statistics  
Frances Namuswe, PhD  
Chao Wang, PhD

B. Pharmacology/Toxicology
Natalie Simpson, PhD

C. Clinical Immunogenicity
Steven Bowen, PhD

D. Clinical Pharmacology
Vicky Hsu, PhD

E. Clinical Efficacy
Lola Luo, PhD

F. Clinical Safety
Lori Ehrlich, MD, PhD

G. Overall Summary
Lori Ehrlich, MD, PhD
Chemistry, Manufacturing, and Controls (CMC)

Frances Namuswe, PhD
CMC Reviewer, Office of Biotechnology Products
U.S. Food and Drug Administration

Chao Wang, PhD
CMC Statistical Reviewer, Office of Biostatistics
U.S. Food and Drug Administration
Erythropoietin (EPO) Mechanism of Action (MOA)

- Endogenous EPO is produced in the kidney and stimulates production of red blood cells (RBCs).
- EPO binds to the EPO receptor on erythroid precursor cells.
- Receptor binding initiates signal transduction that leads to survival, proliferation and differentiation of erythroid progenitor cells into RBCs.
- Reticulocyte count and hemoglobin levels are pharmacodynamics markers.
- MOA is the same for endogenous and recombinant EPO.
Erythropoietin (EPO) Structure

- Glycosylation impacts the half life of circulating EPO

Erythropoietin (EPO) Structure

- Glycosylation = ~40% of EPO molecular weight

Examples of EPO Glycan Heterogeneity

- Figure excerpted from Applicant’s 351 (k) BLA submission
- Figure drawn by FDA reviewer based on Consortium for Functional Glycomics glycan nomenclature
Studies Reviewed

Analytical Similarity
• Physicochemical characterization
• Functional activity

Pharmacokinetic/Pharmacodynamic Similarity
• EPOE-12-02
• EPOE-14-01*

Animal Studies
• 70882
• 60486

Additional Clinical Studies
• EPOE-10-13*
• EPOE-10-01*

* Studies reviewed to support clinical immunogenicity assessment

All studies used US-licensed Epogen/Procrit as comparator
# Quality Attributes Evaluated

<table>
<thead>
<tr>
<th><strong>Primary structure</strong></th>
<th><strong>Glycosylation</strong></th>
<th><strong>Product related species</strong></th>
<th><strong>Drug product attributes</strong></th>
<th><strong>Stability</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>• Amino acid sequence</td>
<td>• N-glycan site occupancy</td>
<td>• Oxidation (Met, Trp)</td>
<td>• Epo content</td>
<td>• Degradation profiles under accelerated and stress conditions</td>
</tr>
<tr>
<td>• Disulfide bonds</td>
<td>• N-glycan antennarity</td>
<td>• Deamidation (Asn, Glu)</td>
<td>• Sub-visible particles</td>
<td></td>
</tr>
<tr>
<td>• Sites of post-translational modification</td>
<td>• Lactosamine repeats</td>
<td>• Asp isomerization</td>
<td>• Container volume</td>
<td></td>
</tr>
<tr>
<td>• Free thiols</td>
<td>• N- and O-acetylation</td>
<td>• Trisulfide species</td>
<td>• Total activity per vial</td>
<td></td>
</tr>
<tr>
<td>• Molecular weight</td>
<td>• N-glycan fucosylation</td>
<td>• Disulfide scrambling</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Higher order structure</strong></td>
<td>• Sialic acid (total, distribution, types)</td>
<td>• Dimers and high-molecular weight species (HMWS)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Secondary structure</td>
<td>• O-site occupancy and O-glycan profile</td>
<td>• Inactive protein variants</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Tertiary structure</td>
<td>• Monosaccharide comp.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Whole protein Molecular weight</td>
<td>• α-Gal-1,3-Gal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Biological activity</strong></td>
<td>• Isoform distribution</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• In vivo activity</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Specific in vivo activity</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• In vitro activity</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Specific in vitro activity, Receptor binding</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Multiple orthogonal methods were used for most attributes
- Removal of human serum albumin (HSA) in US-Epogen/Procrit needed for several methods
Product Lots Used and Data Analysis

<table>
<thead>
<tr>
<th>Product</th>
<th>Number of lots</th>
</tr>
</thead>
<tbody>
<tr>
<td>“Epoetin Hospira” drug product</td>
<td>35</td>
</tr>
<tr>
<td>“Epoetin Hospira” drug substance</td>
<td>9</td>
</tr>
<tr>
<td>US-Epogen/Procrit</td>
<td>54</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Attribute Assessment</th>
<th>Statistical tools</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tier 1</td>
<td>Equivalence testing</td>
</tr>
<tr>
<td>Tier 2</td>
<td>Quality ranges</td>
</tr>
<tr>
<td>Tier 3</td>
<td>Graphical comparison</td>
</tr>
</tbody>
</table>

- Lots used in clinical studies and proposed commercial process were included in analytical similarity assessment.
- Applicant’s comparative analysis was supported by statistical analysis.
- FDA’s analysis also included independent statistical analysis.
### Analytical Similarity Summary

<table>
<thead>
<tr>
<th>Quality Attribute</th>
<th>Supports a Demonstration of Highly Similar</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary structure</td>
<td>Yes-same amino acid sequence</td>
</tr>
<tr>
<td>Secondary &amp; Tertiary structure</td>
<td>Yes</td>
</tr>
<tr>
<td>Overall Glycosylation</td>
<td>Yes (#)</td>
</tr>
<tr>
<td>Protein content</td>
<td>Yes</td>
</tr>
<tr>
<td>In vivo activity</td>
<td>Yes</td>
</tr>
<tr>
<td>In vitro activity</td>
<td>Yes</td>
</tr>
<tr>
<td>Receptor binding</td>
<td>Yes</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Quality Attribute</th>
<th>Supports a Demonstration of Highly Similar</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dimers &amp; High Molecular Weight Species</td>
<td>Yes</td>
</tr>
<tr>
<td>Oxidized species</td>
<td>Yes</td>
</tr>
<tr>
<td>Deamidated species</td>
<td>Yes</td>
</tr>
<tr>
<td>Asp isomerization</td>
<td>Yes</td>
</tr>
<tr>
<td>Disulfide scrambling</td>
<td>Yes</td>
</tr>
<tr>
<td>Trisulfide species</td>
<td>Yes (#)</td>
</tr>
<tr>
<td>Sub-visible particles</td>
<td>Yes</td>
</tr>
<tr>
<td>Stability profiles</td>
<td>Yes</td>
</tr>
</tbody>
</table>

# Differences in the levels of some glycosylation species and Cys29-Cys33 trisulfide species did not preclude a demonstration that “Epoetin Hospira” is highly similar to US-Epogen/Procrit
Glycosylation Profile

- Same glycosylation sites, occupancy & species
- Minor differences in amounts of some species observed

HILIC-UPLC-FLD Chromatograms of Native N-glycans

Figure excerpted from Applicant’s 351(k) BLA submission
Addressing Glycosylation Differences

• EPO glycosylation is important for in vivo biological activity

• Potential impact of glycosylation differences on biological activity primarily evaluated using a sensitive mouse-based assay

• Assessment of biological activity and receptor binding using in vitro cell-based and receptor binding assays provided additional data

• Differences in glycosylation did not result in an observable net effect on biological activity or the intrinsic properties of the molecule

• In vivo biological activity and in vitro specific activity of “Epoetin Hospira” and US-licensed Epogen/Procrit were assessed by Tier 1 equivalence testing
Statistical Equivalence Test

- **MeanDif** = Mean(Test) – Mean (Reference)
- $\sigma_R$: standard deviation of reference product
- The hypotheses:

<table>
<thead>
<tr>
<th>Null</th>
<th>$\text{MeanDif} \leq -1.5\sigma_R \text{ or } \text{MeanDif} \geq 1.5\sigma_R$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alternative</td>
<td>$-1.5\sigma_R &lt; \text{MeanDif} &lt; 1.5\sigma_R$</td>
</tr>
</tbody>
</table>

- Test and reference pass the equivalence test if

  ![90% CI Diagram](image)
In Vivo Biological Activity by a Normocythemic Mouse Model

<table>
<thead>
<tr>
<th>Mean difference</th>
<th>90% CI for mean difference</th>
<th>Equivalence margin</th>
<th>Pass equivalence test?</th>
</tr>
</thead>
<tbody>
<tr>
<td>-2.82</td>
<td>(-7.29, 1.65)</td>
<td>(-11.12, 11.12)</td>
<td>Yes</td>
</tr>
</tbody>
</table>
In Vitro Specific Activity by a Cell-Based Assay

<table>
<thead>
<tr>
<th>Mean difference</th>
<th>90% CI for mean difference</th>
<th>Equivalence margin</th>
<th>Pass equivalence test?</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.23</td>
<td>(1.36, 5.1)</td>
<td>(-5.94, 5.94)</td>
<td>Yes</td>
</tr>
</tbody>
</table>
Addressing Cys29-Cys33 Trisulfide Differences

• “Epoetin Hospira” contains 4.5% more Cys29-Cys33 trisulfide than US-Epogen/Procrit

• Species form by insertion of an extra sulfur atom into the Cys29-Cys33 EPO disulfide bond

• This difference is not expected to have clinical impact:
  o >10% Cys29-Cys33 trisulfide content did not result in differences in either in vivo or in vitro specific activity in an earlier version of “Epoetin Hospira”
  o Literature indicates that trisulfide species can convert to disulfide species in vivo
CMC Conclusions

The totality of the analytical similarity data supports a conclusion that “Epoetin Hospira” is highly similar to US-licensed Epogen/Procrit notwithstanding minor differences in clinically inactive components.
Pharmacology/Toxicology

Natalie Simpson, PhD
Pharmacology/Toxicology Reviewer
Division of Hematology Oncology Toxicology
U.S. Food and Drug Administration
Overview

• Comparative animal studies may support the similarity of a proposed product to a reference product.
  – *FDA Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product*

• Animal studies will be discussed for completeness. However, these studies were not designed to support a demonstration of biosimilarity.

• Comparative animal studies submitted for “Epoetin Hospira” and US-Epogen/Procrit:
  – Study 70882: 13-week subcutaneous (SC) repeat dose toxicology/pharmacokinetic (PK) in rats
  – Study 60486: 13-week intravenous (IV) repeat dose toxicology/PK in dogs

• The rat and dog are appropriate species based on the mechanism of action of EPO; however, immunogenicity is associated with long-term repeat SC dosing of human EPO in rats.
## Conclusions from Animal Studies

<table>
<thead>
<tr>
<th>Study Title</th>
<th>Test Article</th>
<th>Doses (IU/kg 3x/week)</th>
<th>Endpoints</th>
<th>PD</th>
<th>PK</th>
<th>Toxicity**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study 70882: “Epoetin Hospira”: A 13-Week <strong>Subcutaneous</strong> Repeat Dose Comparative Toxicity Study Followed by a 4-Week Recovery Period in Sprague-Dawley Rats</td>
<td>“Epoetin Hospira”</td>
<td>150, 450, 1500/900</td>
<td>↓ PD activity with US-Epogen</td>
<td>↓ Exposure, ↑ ADA with US-Epogen</td>
<td>No difference between arms</td>
<td></td>
</tr>
<tr>
<td></td>
<td>US-Epogen/Procrit</td>
<td>150, 450, 1500/900</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study 60486: “Epoetin Hospira”: A 13-Week <strong>Intravenous</strong> Repeat Dose Comparative Toxicity Study Followed by a 4-Week Recovery Period in Beagle Dogs</td>
<td>“Epoetin Hospira”</td>
<td>150, 450, 1500/900</td>
<td>↑ PD activity for both test articles</td>
<td></td>
<td>↓ Exposure with “Epoetin Hospira”*</td>
<td>No difference between arms</td>
</tr>
<tr>
<td></td>
<td>US-Epogen/Procrit</td>
<td>150, 450, 1500/900</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

PD: pharmacodynamics; PK: toxicokinetics; ADA: anti-drug antibodies
* = within the range of individual animal variability
** = examples of toxicities include multi-organ inflammation, hemorrhage, and necrosis
Pharmacology/Toxicology Summary

• In stepwise evidence development, the differences observed from the perspective of Pharmacology/Toxicology would be addressed by subsequent clinical studies.

• Immunogenicity in animals is not predictive of immunogenicity in humans.

• In general, there were no major differences in the toxicity profile between “Epoetin Hospira” and US-Epogen/Procrit.
Clinical Immunogenicity

Steven Bowen, PhD
Immunogenicity Reviewer
Office of Biotechnology Products
U.S. Food and Drug Administration
Immunogenicity risk of Erythropoiesis-Stimulating Agents (ESA)

• Therapeutic proteins have the potential to induce anti-drug antibodies (ADA) that can impact the safety and efficacy of the drug.

• Erythropoietin is a non-redundant critical growth factor.

• Precedent from other ESAs showed that changes to critical product attributes and impurities can lead to the development of neutralizing antibodies (NAbs) and onset of pure red cell aplasia (PRCA) in patients.

• Is “Epoetin Hospira” similar to US-Epogen/Procrit with respect to immunogenicity, particularly NAbs, supporting a demonstration of no clinically meaningful differences?
Clinical Immunogenicity Data

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Design</th>
<th>Route</th>
<th>Number</th>
<th>Subjects</th>
<th>Dose</th>
<th>Schedule</th>
<th>Primary Endpoint</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPOE-12-02</td>
<td>Cross-over</td>
<td>Subcutaneous</td>
<td>81</td>
<td>Healthy subjects</td>
<td>100 U/kg</td>
<td>Single dose</td>
<td>PK and PD similarity (reticulocyte count)</td>
</tr>
<tr>
<td>EPOE-14-01</td>
<td>Parallel</td>
<td>Subcutaneous</td>
<td>129</td>
<td>Healthy subjects</td>
<td>100 U/kg</td>
<td>3 times / week for 4 weeks</td>
<td>PD similarity (Hb)</td>
</tr>
<tr>
<td>EPOE-10-13</td>
<td>Parallel</td>
<td>Subcutaneous</td>
<td>246</td>
<td>Patients with CKD on HD</td>
<td>Variable</td>
<td>1-3 times / week</td>
<td>Mean weekly Hb Mean weekly dose</td>
</tr>
<tr>
<td>EPOE-10-01</td>
<td>Parallel</td>
<td>Intravenous</td>
<td>612</td>
<td>Patients with CKD on HD</td>
<td>Variable</td>
<td>1-3 times / week</td>
<td>Mean weekly Hb Mean weekly dose</td>
</tr>
</tbody>
</table>

CKD: chronic kidney disease  
PK: pharmacokinetics  
PD: pharmacodynamics  
Hb: hemoglobin  
HD: hemodialysis

Serum samples were tested for ADA using a strategy consistent with FDA Draft Guidance for Industry: *Assay Development and Validation for Immunogenicity Testing of Therapeutic Protein Products* (April 2016)
Clinical Incidence of ADA for “Epoetin Hospira” and US-Epogen

<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>Baseline ADA</th>
<th>Treatment-Induced ADA</th>
<th>NAbs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPOE-10-01 (CKD; intravenous)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>“Epoetin Hospira”</td>
<td>301</td>
<td>0.7%</td>
<td>0.4%</td>
<td>0.0%</td>
</tr>
<tr>
<td>US-Epogen</td>
<td>304</td>
<td>1.1%</td>
<td>0.4%</td>
<td>0.0%</td>
</tr>
<tr>
<td><strong>EPOE-10-13 (CKD; subcutaneous)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>“Epoetin Hospira” (Titration)</td>
<td>80</td>
<td>1.4%</td>
<td>0.0%</td>
<td>0.0%</td>
</tr>
<tr>
<td>US-Epogen (Titration)</td>
<td>86</td>
<td>1.3%</td>
<td>0.0%</td>
<td>0.0%</td>
</tr>
<tr>
<td>“Epoetin Hospira” (Maintenance)</td>
<td>122</td>
<td>0.9%</td>
<td>1.0%</td>
<td>0.0%</td>
</tr>
<tr>
<td>US-Epogen (Maintenance)</td>
<td>122</td>
<td>1.0%</td>
<td>0.9%</td>
<td>0.0%</td>
</tr>
<tr>
<td><strong>EPOE-14-01 (Healthy subjects; SC)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>“Epoetin Hospira”</td>
<td>66</td>
<td>4.5%</td>
<td>3.0%</td>
<td>0.0%</td>
</tr>
<tr>
<td>US-Epogen</td>
<td>63</td>
<td>3.2%</td>
<td>3.2%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

ADA: Anti-drug Antibodies; NAbs: Neutralizing antibodies
Immunogenicity Conclusions

• Immunogenicity of “Epoetin Hospira” and US-Epogen was compared in 3 multiple-dose, parallel-arm studies in 849 patients with CKD (EPOE-10-01 and EPOE-10-13) and 129 healthy subjects (EPOE-14-01).

• ADA (anti-drug antibodies) in serum samples were tested using adequately validated assays.

• Similar rates of binding ADA were observed between the “Epoetin Hospira” and US-Epogen treatment groups in patients with CKD and healthy subjects.

• No neutralizing antibodies were observed in subjects treated with “Epoetin Hospira” or US-Epogen.

• These data show no increase in immunogenicity risk and support a conclusion that there are no clinically meaningful differences between "Epoetin Hospira" and US-Epogen.
Clinical Pharmacology

Vicky Hsu, PhD
Clinical Pharmacology Reviewer
Office of Clinical Pharmacology
U.S. Food and Drug Administration
Clinical Pharmacology Overview

• The goal of the clinical pharmacology program is to evaluate PK and PD similarity
  – Single-dose pharmacokinetic (PK) and pharmacodynamic (PD) (reticulocyte count) similarity between “Epoetin Hospira” and US-licensed Epogen
  – Multiple-dose PD (hemoglobin level) similarity between “Epoetin Hospira” and US-licensed Epogen

• Review Question
  – Do the clinical pharmacology data submitted in this BLA support a demonstration of no clinically meaningful differences between “Epoetin Hospira” and US-licensed Epogen?
# Clinical Pharmacology Studies

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Design</th>
<th>Route</th>
<th>Number</th>
<th>Subjects</th>
<th>Dose</th>
<th>Schedule</th>
<th>Primary Endpoint</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPOE-12-02</td>
<td>Cross-over</td>
<td>Subcutaneous</td>
<td>81</td>
<td>Healthy subjects</td>
<td>100 U/kg</td>
<td>Single dose</td>
<td>PK and PD similarity (reticulocyte count)</td>
</tr>
<tr>
<td>EPOE-14-01</td>
<td>Parallel</td>
<td>Subcutaneous</td>
<td>129</td>
<td>Healthy subjects</td>
<td>100 U/kg</td>
<td>3 times / week for 4 weeks</td>
<td>PD similarity (Hb)</td>
</tr>
<tr>
<td>EPOE-10-13</td>
<td>Parallel</td>
<td>Subcutaneous</td>
<td>246</td>
<td>Patients with CKD on HD</td>
<td>Variable</td>
<td>1-3 times / week</td>
<td>Mean weekly Hb</td>
</tr>
<tr>
<td>EPOE-10-01</td>
<td>Parallel</td>
<td>Intravenous</td>
<td>612</td>
<td>Patients with CKD on HD</td>
<td>Variable</td>
<td>1-3 times / week</td>
<td>Mean weekly Hb</td>
</tr>
</tbody>
</table>

CKD: chronic kidney disease  
PK: pharmacokinetics  
PD: pharmacodynamics  
Hb: hemoglobin  
HD: hemodialysis
Single-Dose: EPOE-12-02 (SC)  
PK and PD Profile Results

**PK:** post-100 U/kg over 5 days

**PD:** reticulocyte count over 19 days
Single-Dose: EPOE-12-02 (SC) PK and PD Similarity were Met

- **Cmax**: maximum concentration
- **AUC**: area under curve
- **Emax**: maximum effect
- **AUEC**: area under effect curve
- **%Ret**: reticulocyte count as a percentage of erythrocytes

**Geometric Mean Ratio (90% confidence interval)**

- **Cmax**: 1.09 (1.01, 1.18)
- **AUC0-T**: 1.06 (1.01, 1.11)
- **AUC0-inf**: 1.03 (0.97, 1.09)
- **%Ret Emax**: 1.02 (0.99, 1.05)
- **%Ret AUEC**: 1.01 (0.98, 1.05)

Definitions:
- **Cmax**: maximum concentration
- **AUC**: area under curve
- **Emax**: maximum effect
- **AUEC**: area under effect curve
- **%Ret**: reticulocyte count as a percentage of erythrocytes

"Epoetin Hospira" US - Epogen
Multiple-Dose: EPOE-14-01 (SC)
PK and PD Similarity were Met

- Cmax: maximum concentration
- AUC: area under curve
- Emax: maximum effect
- AUEC: area under effect curve
- Hb: hemoglobin level

Geometric Mean Ratio (90% confidence interval)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cmax</td>
<td>0.94 (0.84, 1.05)</td>
</tr>
<tr>
<td>AUC0-T</td>
<td>0.97 (0.90, 1.06)</td>
</tr>
<tr>
<td>Emax</td>
<td>1.00 (0.99, 1.02)</td>
</tr>
<tr>
<td>Hb AUEC0-T</td>
<td>1.00 (0.99, 1.02)</td>
</tr>
</tbody>
</table>

"Epoetin Hospira" US - Epogen
Clinical Pharmacology Summary

• The PK and PD study results support a demonstration of no clinically meaningful differences between “Epoetin Hospira” and US-licensed Epogen.

• The PK and PD study results add to the totality of the evidence to support a demonstration of biosimilarity between “Epoetin Hospira” and US-licensed Epogen.
Clinical Efficacy

Lola Luo, PhD
Clinical Statistical Reviewer
Division of Oncology and Hematology
Office of Biostatistics
U.S. Food and Drug Administration
## Comparative Clinical Studies

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Design</th>
<th>Route</th>
<th>Number</th>
<th>Subjects</th>
<th>Dose</th>
<th>Schedule</th>
<th>Primary Endpoint</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPOE-12-02</td>
<td>Cross-over</td>
<td>Subcutaneous</td>
<td>81</td>
<td>Healthy subjects</td>
<td>100 U/kg</td>
<td>Single dose</td>
<td>PK and PD similarity (reticulocyte count)</td>
</tr>
<tr>
<td>EPOE-14-01</td>
<td>Parallel</td>
<td>Subcutaneous</td>
<td>129</td>
<td>Healthy subjects</td>
<td>100 U/kg</td>
<td>3 times / week for 4 weeks</td>
<td>PD similarity (Hb)</td>
</tr>
<tr>
<td>EPOE-10-13</td>
<td>Parallel</td>
<td>Subcutaneous</td>
<td>246</td>
<td>Patients with CKD on HD</td>
<td>Variable</td>
<td>1-3 times / week</td>
<td>Mean weekly Hb</td>
</tr>
<tr>
<td>EPOE-10-01</td>
<td>Parallel</td>
<td>Intravenous</td>
<td>612</td>
<td>Patients with CKD on HD</td>
<td>Variable</td>
<td>1-3 times / week</td>
<td>Mean weekly Hb</td>
</tr>
</tbody>
</table>

CKD: chronic kidney disease  
PK: pharmacokinetics  
PD: pharmacodynamics  
Hb: hemoglobin  
HD: hemodialysis
Good Clinical Practice Compliance
Study Site Closures

• EPOE-10-13 (SC)
  – 3 sites closed during conduct of the study
  – No additional sites identified in post-study GCP assessment
  – 10% (53/556) patients enrolled
  – 8% (20/246) patients in ITT population

• EPOE-10-01 (IV)
  – 7 sites closed during conduct of the study
  – 2 additional sites identified in post-study GCP assessment
  – 14% (140/1017) patients enrolled
  – 11% (65/612) patients in ITT population

GCP: Good Clinical Practice, ITT: intent to treat
SC: subcutaneous, IV: intravenous
Statistical Analysis Plan (SAP)

• Co-Primary Endpoints for the Comparative Clinical Studies:
  – Mean weekly hemoglobin (Hb) level during the last 4 weeks of the double-blind Maintenance Period.
  – Mean weekly dose per kg body weight during the last 4 weeks of the double-blind Maintenance Period.

• Equivalence Margin
  – Hb: ±0.5g/dL
  – Dose: ±45 U/kg/week

• Randomization:
  – 1:1 ratio
  – Double blind
  – Stratification by the titration period study drug dose (EPOE-10-13 only)
## Sample Size Planned

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Power</th>
<th>Equivalence Margin</th>
<th>SD</th>
<th>Predicted % Missing</th>
<th>Planned N</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPOE-10-13 (SC)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hb (g/dL)</td>
<td>90%</td>
<td>± 0.5</td>
<td>0.94</td>
<td>35%</td>
<td>288</td>
</tr>
<tr>
<td>Dose (U/kg/week)</td>
<td>90%</td>
<td>± 45</td>
<td>78</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EPOE-10-01 (IV)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hb (g/dL)</td>
<td>90%</td>
<td>± 0.5</td>
<td>1.37</td>
<td>30%</td>
<td>564</td>
</tr>
<tr>
<td>Dose (U/kg/week)</td>
<td>90%</td>
<td>± 45</td>
<td>118.11</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Hb: hemoglobin; SC: subcutaneous; IV: intravenous
### Statistical Methods

<table>
<thead>
<tr>
<th>Analysis Population</th>
<th>Description</th>
<th>Clinical Study</th>
<th>“Epoetin Hospira”</th>
<th>US-Epogen /Procrit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intent-to-treat (ITT)</td>
<td>All randomized subjects</td>
<td>EPOE-10-13 (SC)</td>
<td>124</td>
<td>122</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EPOE-10-01 (IV)</td>
<td>306</td>
<td>306</td>
</tr>
<tr>
<td>Good Clinical Practice (GCP)</td>
<td>ITT population excluding subjects from the closed sites</td>
<td>EPOE-10-13 (SC)</td>
<td>112</td>
<td>114</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EPOE-10-01 (IV)</td>
<td>268</td>
<td>279</td>
</tr>
</tbody>
</table>

- A hierarchical testing procedure is used for the co-primary endpoints (mean Hb level → mean weekly dose/kg)
- An analysis of covariance (ANCOVA):
  - Treatment as the factor
  - Baseline value (Hb or dose) as covariate
Co-primary Endpoint: Difference in Mean Weekly Hemoglobin

**EPOE-10-13 (subcutaneous)**

<table>
<thead>
<tr>
<th></th>
<th>ITT</th>
<th>GCP</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.04 (-0.13, 0.21)</td>
<td><img src="checkmark.png" alt="Green Check" /></td>
<td><img src="checkmark.png" alt="Green Check" /></td>
</tr>
</tbody>
</table>

**EPOE-10-01 (intravenous)**

<table>
<thead>
<tr>
<th></th>
<th>ITT</th>
<th>GCP</th>
</tr>
</thead>
<tbody>
<tr>
<td>-0.12 (-0.22, -0.01)</td>
<td><img src="checkmark.png" alt="Green Check" /></td>
<td><img src="checkmark.png" alt="Green Check" /></td>
</tr>
</tbody>
</table>

*Difference, in g/dL (90% confidence interval)*

*ITT: intent-to-treat
GCP: Good Clinical Practice*
Co-primary Endpoint: Difference in Mean Weekly Dose

EPOE-10-13 (subcutaneous)

- ITT
  - Difference: -2.3 (-12.5, 7.9)
  - GCP
  - Difference: 0.8 (-8.9, 10.4)

EPOE-10-01 (intravenous)

- ITT
  - Difference: 0.4 (-8.7, 9.4)
  - GCP
  - Difference: 0.3 (-9.0, 9.6)

ITT: intent-to-treat
GCP: Good Clinical Practice

Difference, in U/kg/week (90% confidence interval) ("Epoetin Hospira" - US-Epogen)
Efficacy Conclusions

• The 90% CIs for the difference between “Epoetin Hospira” and US-licensed Epogen/Procrit for both primary endpoints are within the equivalence margins for both EPOE-10-13 and EPOE-10-01 studies.

• These results were consistent between different sensitivity analyses and subgroups.

• These data support a demonstration of no clinically meaningful differences between “Epoetin Hospira” and US-licensed Epogen/Procrit.
Clinical Safety

Lori Ehrlich, MD, PhD
Medical Officer
Division of Hematology Products
U.S. Food and Drug Administration
## Safety analysis
### EPOE-10-13 (SC) – maintenance period

<table>
<thead>
<tr>
<th></th>
<th>Original Analysis</th>
<th>Closed Sites Excluded</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>“Epoetin Hospira”</td>
<td>US-Epogen/ Procrit</td>
</tr>
<tr>
<td></td>
<td>N = 122 n (%)</td>
<td>N = 122 n (%)</td>
</tr>
<tr>
<td>Subjects Reporting at Least One TEAE</td>
<td>85 (70)</td>
<td>86 (71)</td>
</tr>
<tr>
<td>Subjects Reporting at Least One Serious TEAE</td>
<td>23 (19)</td>
<td>33 (27)</td>
</tr>
<tr>
<td>Subjects Discontinuing Study Drug due to a TEAE</td>
<td>4 (3)</td>
<td>4 (3)</td>
</tr>
<tr>
<td>Subjects Reporting an TEAE Resulting in Death</td>
<td>3 (3)</td>
<td>2 (2)</td>
</tr>
</tbody>
</table>

SC: subcutaneous
TEAE: treatment-emergent adverse event
## Safety analysis

**EPOE-10-01 (IV)**

<table>
<thead>
<tr>
<th></th>
<th>Original Analysis</th>
<th>Closed Sites Excluded</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>“Epoetin Hospira”</td>
<td>US-Epogen/ Procrit</td>
</tr>
<tr>
<td></td>
<td>N = 301 n (%)</td>
<td>N = 304 n (%)</td>
</tr>
<tr>
<td></td>
<td>“Epoetin Hospira”</td>
<td>US-Epogen/ Procrit</td>
</tr>
<tr>
<td></td>
<td>N = 264 n (%)</td>
<td>N = 277 n (%)</td>
</tr>
<tr>
<td>Subjects Reporting at Least One TEAE</td>
<td>232 (77)</td>
<td>229 (75)</td>
</tr>
<tr>
<td>Subjects Reporting at Least One Serious TEAE</td>
<td>75 (25)</td>
<td>82 (27)</td>
</tr>
<tr>
<td>Subjects Discontinuing Study Drug due to a TEAE</td>
<td>9 (3)</td>
<td>11 (4)</td>
</tr>
<tr>
<td>Subjects Reporting an TEAE Resulting in Death</td>
<td>5 (2)</td>
<td>6 (2)</td>
</tr>
</tbody>
</table>

IV: intravenous  
TEAE: treatment-emergent adverse event
Additional Safety Findings

• Major events of interest (myocardial infarction, stroke, and thromboembolism) were observed in both arms with no imbalances.

• No cases of pure red cell aplasia (PRCA) were observed in these clinical studies.
Safety Conclusions

• Safety monitoring in clinical studies was adequate.

• No imbalances in safety profiles between patients who received “Epoetin Hospira” vs. US-licensed Epogen/Procrit.

• Sensitivity analysis excluding non-GCP compliant sites did not change the overall results.
Extrapolation Across Indications

Proposed indications are the same as US-licensed Epogen/Procrit:

– For the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and not on dialysis to decrease the need for red blood cell (RBC) transfusion

– For the treatment of anemia due to zidovudine administered at $\leq 4200$ mg/week in HIV-infected patients with endogenous serum erythropoietin levels of $\leq 500$ mUnits/mL

– For the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy

– To reduce the need for allogeneic RBC transfusions among patients with perioperative hemoglobin $> 10$ to $\leq 13$ g/dL who are at high risk for perioperative blood loss from elective, noncardiac, nonvascular surgery
Support for Extrapolation

• Mechanism of action is the same across indications

• Similarity has been demonstrated with regard to:
  – Analytical attributes
  – Pharmacokinetics/pharmacodynamics
  – Immunogenicity
  – Efficacy and safety
Overall Summary of FDA Findings
Biosimilarity

• Highly similar to reference product, notwithstanding minor differences in clinically inactive components, and

• No clinically meaningful differences in safety, purity, and potency
Summary of FDA Findings

• Totality of analytical data, based on multiple orthogonal physicochemical and functional methods, support a demonstration of highly similar notwithstanding minor differences in clinically inactive components.

• Clinical data, including pharmacokinetics, pharmacodynamics, efficacy, safety, and immunogenicity data support a demonstration that there are no clinically meaningful differences.

• Residual uncertainties (differences in glycosylation and trisulfide species) were adequately addressed by other data, including clinical data.
Overall Conclusion

• Totality of the evidence supports a demonstration of biosimilarity between “Epoetin Hospira” and US-licensed Epogen/Procrit.

• Extrapolation to all indications for “Epoetin Hospira” is supported by demonstration of biosimilarity and, among other information, the scientific understanding of the mechanism of action across indications.